Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 1,845.00
+7.00 (0.38%)
Aug 25, 2026, 3:30 PM JST
Fuji Pharma Balance Sheet
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 9,952 | 7,245 | 4,585 | 2,324 | 3,546 | 10,199 |
Cash & Short-Term Investments | 9,952 | 7,245 | 4,585 | 2,324 | 3,546 | 10,199 |
Cash Growth | 43.94% | 58.02% | 97.29% | -34.46% | -65.23% | -15.30% |
Accounts Receivable | 19,670 | 17,987 | 18,426 | 16,304 | 12,527 | 11,866 |
Other Receivables | 206 | 296 | 453 | 216 | 134 | 118 |
Receivables | 19,876 | 18,283 | 18,879 | 16,520 | 12,661 | 11,984 |
Inventory | 23,557 | 21,215 | 18,005 | 19,371 | 15,823 | 12,006 |
Other Current Assets | 1,303 | 1,170 | 999 | 899 | 2,697 | 645 |
Total Current Assets | 54,688 | 47,913 | 42,468 | 39,114 | 34,727 | 34,834 |
Property, Plant & Equipment | 20,900 | 20,914 | 20,911 | 20,547 | 18,762 | 14,392 |
Long-Term Investments | 2,508 | 8,308 | 13,036 | 14,702 | 10,211 | 11,265 |
Goodwill | - | - | 88 | 412 | 691 | 865 |
Other Intangible Assets | 13,547 | 13,941 | 12,356 | 10,081 | 9,713 | 1,532 |
Long-Term Deferred Tax Assets | 3,555 | 2,327 | 1,139 | 475 | 1,432 | 1,349 |
Other Long-Term Assets | 3,228 | 2 | 2 | 1 | 2 | 2 |
Total Assets | 98,426 | 93,405 | 90,000 | 85,332 | 75,538 | 64,239 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 5,759 | 4,570 | 4,140 | 5,672 | 6,249 | 5,713 |
Accrued Expenses | 1,009 | 1,105 | 560 | 883 | 990 | 982 |
Short-Term Debt | 15,300 | 15,300 | 15,300 | 11,300 | 8,300 | 7,000 |
Current Portion of Long-Term Debt | 1,898 | 1,981 | 7,100 | 5,210 | 2,440 | 1,840 |
Current Portion of Leases | 595 | 582 | 569 | 514 | 377 | 681 |
Current Income Taxes Payable | 1,102 | 963 | 1,567 | 484 | 444 | 823 |
Other Current Liabilities | 7,305 | 6,487 | 6,561 | 5,708 | 5,175 | 3,153 |
Total Current Liabilities | 32,968 | 30,988 | 35,797 | 29,771 | 23,975 | 20,192 |
Long-Term Debt | 7,428 | 8,952 | 1,583 | 8,683 | 11,193 | 6,633 |
Long-Term Leases | 3,673 | 4,122 | 4,702 | 3,241 | 2,259 | 2,508 |
Pension & Post-Retirement Benefits | 2,286 | 2,215 | 2,130 | 1,863 | 1,766 | 1,657 |
Other Long-Term Liabilities | 192 | 222 | 227 | 598 | 541 | 570 |
Total Liabilities | 46,547 | 46,499 | 44,439 | 44,156 | 39,734 | 31,560 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 5,555 | 3,904 | 3,799 | 3,799 | 3,799 | 3,799 |
Additional Paid-In Capital | 6,163 | 4,511 | 4,406 | 4,409 | 4,409 | 4,409 |
Retained Earnings | 36,813 | 36,219 | 34,256 | 29,082 | 26,546 | 24,628 |
Treasury Stock | -480 | -498 | -505 | -567 | -579 | -590 |
Comprehensive Income & Other | 3,824 | 2,767 | 3,602 | 4,451 | 1,627 | 432 |
Total Common Equity | 51,875 | 46,903 | 45,558 | 41,174 | 35,802 | 32,678 |
Minority Interest | 4 | 3 | 3 | 2 | 2 | 1 |
Shareholders' Equity | 51,879 | 46,906 | 45,561 | 41,176 | 35,804 | 32,679 |
Total Liabilities & Equity | 98,426 | 93,405 | 90,000 | 85,332 | 75,538 | 64,239 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 28,894 | 30,937 | 29,254 | 28,948 | 24,569 | 18,662 |
Net Cash (Debt) | -18,942 | -23,692 | -24,669 | -26,624 | -21,023 | -8,463 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -756.35 | -970.86 | -1014.74 | -1095.58 | -865.39 | -315.00 |
Filing Date Shares Outstanding | 26.12 | 24.46 | 24.31 | 24.3 | 24.29 | 24.29 |
Total Common Shares Outstanding | 26.12 | 24.46 | 24.31 | 24.3 | 24.29 | 24.29 |
Working Capital | 21,720 | 16,925 | 6,671 | 9,343 | 10,752 | 14,642 |
Book Value Per Share | 1986.04 | 1917.91 | 1873.87 | 1694.21 | 1473.66 | 1345.50 |
Tangible Book Value | 38,328 | 32,962 | 33,114 | 30,681 | 25,398 | 30,281 |
Tangible Book Value Per Share | 1467.39 | 1347.85 | 1362.03 | 1262.45 | 1045.42 | 1246.81 |
Order Backlog | - | 2,540 | 1,697 | 1,672 | 1,313 | 213 |